

Kallikrein 13 Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP6332a**Specification**

Kallikrein 13 Antibody (Center) Blocking peptide - Product InformationPrimary Accession [Q9UKR3](#)**Kallikrein 13 Antibody (Center) Blocking peptide - Additional Information****Gene ID** 26085**Other Names**

Kallikrein-13, 3421-, Kallikrein-like protein 4, KLK-L4, KLK13, KLKL4

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP6332a was selected from the Center region of human KLK13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Kallikrein 13 Antibody (Center) Blocking peptide - Protein Information**Name** KLK13**Synonyms** KLKL4**Cellular Location**

Secreted.

Tissue Location

Expressed in prostate, breast, testis and salivary gland

Kallikrein 13 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

Kallikrein 13 Antibody (Center) Blocking peptide - Images

Kallikrein 13 Antibody (Center) Blocking peptide - Background

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. Expression of KLK13 is regulated by steroid hormones and may be useful as a marker for breast cancer.

Kallikrein 13 Antibody (Center) Blocking peptide - References

Kapadia, C., et al., Biochem. Biophys. Res. Commun. 323(3):1084-1090 (2004). Petraki, C.D., et al., Prostate Cancer Prostatic Dis. 6(3):223-227 (2003). Chang, A., et al., Br. J. Cancer 86(9):1457-1464 (2002). Chang, A., et al., Anticancer Res. 21(5):3147-3152 (2001). Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).